Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06441747
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-04
First Post:
2024-05-29
Brief Title:
Phase II Study of the Combination of Durvalumab MEDI4736 PDL1 Inhibitor and Olaparib PARP Inhibitor in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab BIL-PPP
Sponsor:
Australasian Gastro-Intestinal Trials Group
Organization:
Australasian Gastro-Intestinal Trials Group
Organization Data
Organization:
Australasian Gastro-Intestinal Trials Group
Class:
NETWORK
Study ID:
BIL-PPP
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Australasian Gastro-Intestinal Trials Group
Lead Sponsor Class:
NETWORK
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
| Wayne Elphinstone Research Fund | UNKNOWN |